参考文献: 1. Zhang W, Ramdas L, Shen W, et al. 2003. Cancer Biol Ther, 2: 572-8. 2. Takubo T, Kumura T, Nishiki S, et al. 2000. Acta Haematol, 103: 165-7. 3. Lautrette C, Loum-Ribot E, Petit D, et al. 2006. Apoptosis, 11: 1195-204. 4. Kovacic N, Grcevic D, Katavic V, et al. 2010. Lab Invest, 90: 402-13. 5. Kaufmann T, Strasser A, Jost PJ. 2012. Cell Death Differ, 19: 42-50.
Gene IDs: 355
纯度: > 95 % by SDS-PAGE and HPLC analyses.
来源: Escherichia coli.
内毒素水平: Less than 1 EU/μg of Recombinant HumansFasR/TNFRSF6 as determined by LAL method.
活性: Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit the cytotoxicity of Jurkat cells is between 10-15 μg/ml in the presence of 2 ng/ml of Recombinant HumanFas Ligand.
形态: Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
溶解方法: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
储存/保存方法: This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.